Last Updated:
10 Mar 2026, 03:29:14 PM (IST)
Bal Pharma Limited
NSE: BALPHARMA BSE: BALPHARMA
NSE
70.99
1.88 (2.72%)
Prev Close
69.11
Open Price
70
Volume
16,312
Today Low / High
67.6 / 73.41
52 WK Low / High
65.7 / 128.74
Range
67 - 75
BSE
71.86
2.06 (2.95%)
Prev Close
69.8
Open Price
70.8
Volume
656
Today Low / High
67.15 / 72
52 WK Low / High
64 / 128.86
Range
68 - 75
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 70.99 (target range: 67 - 75), reflecting a change of 1.88 (2.7203%). On the BSE, it is listed at 71.86 (target range: 68 - 75), showing a change of 2.06 (2.95129%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Bal Pharma Limited Graph
Bal Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bal Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 70.99, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 71.86 | 72.58 | 65.32 - 79.84 |
| 73.30 | 58.64 - 87.96 | ||
| 74.02 | 51.81 - 96.22 | ||
| Bearish Scenario | 71.86 | 71.14 | 64.03 - 78.26 |
| 70.42 | 56.34 - 84.51 | ||
| 69.70 | 48.79 - 90.62 |
Overview of Bal Pharma Limited
ISIN
INE083D01012
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
9,510
Market Cap
1,189,607,556
Last Dividend
1.2
Official Website
IPO Date
2006-05-08
DCF Diff
124.95
DCF
-53
Financial Ratios Every Investor Needs
Stock Dividend of BALPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-09-18 | September 18, 25 | 1.2 | 1.2 | 2025-09-18 | 2025-10-10 | |
| 2024-09-17 | September 17, 24 | 1.2 | 1.2 | 2024-09-18 | 2024-10-25 | |
| 2023-09-18 | September 18, 23 | 1 | 1 | 2023-09-18 | 2023-10-25 | |
| 2022-09-13 | September 13, 22 | 1 | 1 | 2022-09-14 | 2022-10-19 | |
| 2021-09-16 | September 16, 21 | 1 | 1 | 2021-09-17 | 2021-10-24 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 303.08 Cr | 242.84 Cr | 73.02 Cr | 0.2409 | 3.25 Cr | 4.62 Cr | 19.79 Cr | 7.22 Cr | 4.56 | 31.76 Cr | 0.0238 |
| 2024-03-31 | 339.22 Cr | 262.20 Cr | 77.02 Cr | 0.2270 | 5.07 Cr | 4.27 Cr | 21.46 Cr | 7.39 Cr | 4.70 | 32.02 Cr | 0.0218 |
| 2023-03-31 | 304.22 Cr | 172.77 Cr | 125.46 Cr | 0.4124 | 4.92 Cr | 3.42 Cr | 17.72 Cr | 2.57 Cr | 1.64 | 24.50 Cr | 0.0085 |
| 2022-03-31 | 281.21 Cr | 169.73 Cr | 111.48 Cr | 0.3964 | 3.20 Cr | 2.71 Cr | 14.92 Cr | 5.61 Cr | 3.79 | 23.97 Cr | 0.0200 |
| 2021-03-31 | 246.94 Cr | 151.23 Cr | 99.30 Cr | 0.4021 | 3.17 Cr | 2.13 Cr | 14.06 Cr | 4.74 Cr | 3.34 | 25.78 Cr | 0.0192 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 8.05 Cr | 335.69 Cr | 258.29 Cr | 77.4159 Cr | 150.41 Cr | 142.36 Cr | 103.02 Cr | 73.78 Cr | 0.00 Cr | 0.00 Cr | 7.13 Cr | 219.5003 Cr |
| 2024-03-31 | 4.20 Cr | 319.53 Cr | 250.26 Cr | 69.2943 Cr | 142.25 Cr | 138.05 Cr | 87.81 Cr | 64.25 Cr | 0.00 Cr | 0.45 Cr | -6.19 Cr | 203.0424 Cr |
| 2023-03-31 | 1.49 Cr | 313.17 Cr | 249.47 Cr | 63.7891 Cr | 133.08 Cr | 129.51 Cr | 98.01 Cr | 62.18 Cr | 12.23 Cr | 0.45 Cr | -4.09 Cr | 209.3344 Cr |
| 2022-03-31 | 1.11 Cr | 260.53 Cr | 202.04 Cr | 58.6268 Cr | 106.66 Cr | 105.54 Cr | 74.40 Cr | 57.28 Cr | 6.28 Cr | 1.83 Cr | 2.34 Cr | 165.6448 Cr |
| 2021-03-31 | 1.02 Cr | 240.08 Cr | 186.73 Cr | 53.5814 Cr | 111.95 Cr | 110.92 Cr | 60.39 Cr | 57.51 Cr | 11.23 Cr | 1.95 Cr | 2.87 Cr | 152.5329 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4.2322 Cr | -15.6533 Cr | 9.0120 Cr | -14.5546 Cr | 3.7348 Cr | 8.0505 Cr | -18.7868 Cr | 7.2154 Cr | 10.7813 Cr | -1.9105 Cr | -15.2109 Cr |
| 2024-03-31 | 22.8058 Cr | -18.8909 Cr | -1.2063 Cr | 11.8258 Cr | 2.7087 Cr | 4.1958 Cr | -10.9800 Cr | 7.3923 Cr | 16.1876 Cr | -1.5690 Cr | 10.1936 Cr |
| 2023-03-31 | -1.8435 Cr | -22.1824 Cr | 24.4002 Cr | -16.4889 Cr | 0.3744 Cr | 1.4871 Cr | -14.6454 Cr | 4.7485 Cr | 35.4173 Cr | -1.5572 Cr | -23.6094 Cr |
| 2022-03-31 | 27.7084 Cr | -9.4848 Cr | -18.1343 Cr | 19.2391 Cr | 0.0893 Cr | 1.1128 Cr | -8.4693 Cr | 9.1825 Cr | -6.2486 Cr | -1.4822 Cr | -14.0103 Cr |
| 2021-03-31 | 21.7812 Cr | -4.9805 Cr | -16.6324 Cr | 18.3678 Cr | 0.1647 Cr | 1.0234 Cr | -3.4134 Cr | 4.1027 Cr | -12.9225 Cr | -0.2913 Cr | 7.3261 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 87.69 Cr | 66.71 Cr | 20.98 Cr | 0.2392 | 6.32 Cr | 1.78 Cr | 1.12 | 9.55 Cr | 0.0203 |
| 2025-09-30 | 74.02 Cr | 39.94 Cr | 34.09 Cr | 0.4605 | 3.46 Cr | 0.71 Cr | 0.45 | 6.85 Cr | 0.0096 |
| 2025-06-30 | 65.87 Cr | 33.54 Cr | 32.33 Cr | 0.4908 | 3.54 Cr | 0.20 Cr | 0.13 | 6.78 Cr | 0.0030 |
| 2025-03-31 | 81.88 Cr | 61.64 Cr | 20.23 Cr | 0.2471 | 5.46 Cr | 5.43 Cr | 3.73 | 8.72 Cr | 0.0664 |
| 2024-12-31 | 73.15 Cr | 36.85 Cr | 36.30 Cr | 0.4962 | 5.07 Cr | 0.48 Cr | 0.33 | 8.26 Cr | 0.0066 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 1.58 Cr | 9.08 Cr | 10.66 Cr | 92.01 Cr | 112.69 Cr | 245.01 Cr | 79.21 Cr | 349.37 Cr | 271.04 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 10.52 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -77.40 Cr |
| 2025-03-31 | 8.05 Cr | 8.66 Cr | 10.52 Cr | 93.58 Cr | 103.02 Cr | 234.87 Cr | 73.78 Cr | 335.69 Cr | 258.29 Cr |
| 2024-12-31 | 1.75 Cr | 8.66 Cr | 10.41 Cr | 92.44 Cr | 103.02 Cr | 234.87 Cr | 73.78 Cr | 335.69 Cr | 258.29 Cr |
| 2024-09-30 | 1.95 Cr | 11.00 Cr | 26.16 Cr | 2.32 Cr | 89.87 Cr | 248.21 Cr | 65.65 Cr | 339.51 Cr | 270.75 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 2.96 Cr | 4.41 Cr | 1.36 Cr | -6.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3.84 Cr | 0.56 Cr |
| 2024-12-31 | 2.96 Cr | 4.41 Cr | 1.36 Cr | -6.50 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3.84 Cr | 0.56 Cr |
| 2024-09-30 | 1.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 0.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Senior General Manager
N Subrahmanyeswara Rao
Gender: Not Specified
Year Born: 1972
General Manager of Purchase
Bidyut Kumar Bhattacharrya
Gender: Not Specified
Year Born: 1976
Company Secretary & Compliance Officer
Abdul Basith
Gender: male
Year Born:
Chief Financial Officer
Daddanala Venkat Bharath Bhushan
Gender: male
Year Born: 1989
Assistant Vice President of Sales & Marketing
D. L. Bhat
Gender: male
Year Born: 1963
Whole Time Director
Himesh Virupakshaya
Gender: male
Year Born: 1961
Deputy GM of Internal Audit, Legal and Compliances & Non-Executive and Non-Independent Director
Ravindra Kumar Kothari
Gender: male
Year Born: 1955
Chief Operating Officer
Archana Dubey Mitra
Gender: female
Year Born: 1974
MD & Executive Director
Shailesh Dheerajmal Siroya
Gender: male
Year Born: 1966
General Manager
Ezaz Kaseem Azmi
Gender: Not Specified
Year Born: 1982
FAQs about Bal Pharma Limited
Who is the CEO of the company?
The CEO is Shailesh Dheerajmal Siroya.
What is the current market price of the stock?
The current price is ₹74.72.
What is the 52-week price range?
The range is ₹65.7-128.74.
What is the market capitalization of the company?
The market capitalization is ₹118.96 crores.
What is the dividend yield?
The dividend yield is 1.61%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 14.64.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bal Pharma Limited (ISIN: INE083D01012) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹118.96 crores and an average daily volume of 9,510 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.2.